Selatogrel: Difference between revisions
CSV import |
CSV import |
||
| Line 9: | Line 9: | ||
}} | }} | ||
'''Selatogrel''' is a novel [[antiplatelet drug]] that acts as a | '''Selatogrel''' is a novel [[antiplatelet drug]] that acts as a [[P2Y12 receptor]] antagonist. It is being developed for the treatment of [[acute coronary syndrome]] (ACS) and other conditions where inhibition of platelet aggregation is desired. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Selatogrel works by inhibiting the P2Y12 receptor, a key receptor involved in the activation of [[platelets]]. | Selatogrel works by selectively inhibiting the [[P2Y12 receptor]], a key receptor involved in the activation of [[platelets]]. By blocking this receptor, selatogrel prevents the binding of [[adenosine diphosphate]] (ADP), a potent platelet activator, thereby reducing platelet aggregation and thrombus formation. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug | Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug is designed to provide quick and effective platelet inhibition, which is crucial in the acute management of thrombotic events. | ||
==Clinical Development== | ==Clinical Development== | ||
Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. | Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. Preliminary studies have shown promising results, with rapid onset of action and significant inhibition of platelet aggregation. | ||
==Potential Benefits== | ==Potential Benefits== | ||
The rapid | The rapid action of selatogrel makes it a potentially valuable option in emergency settings where quick platelet inhibition is necessary. Its subcutaneous route of administration offers a convenient alternative to oral antiplatelet agents, especially in patients who are unable to take oral medications. | ||
==Side Effects== | ==Side Effects== | ||
As with other antiplatelet | As with other antiplatelet agents, the primary side effect of selatogrel is an increased risk of bleeding. Other potential side effects include [[bruising]], [[nausea]], and [[headache]]. | ||
==Related | ==Related pages== | ||
* [[Antiplatelet drug]] | * [[Antiplatelet drug]] | ||
* [[P2Y12 receptor]] | * [[P2Y12 receptor]] | ||
* [[Acute coronary syndrome]] | * [[Acute coronary syndrome]] | ||
* [[Platelet]] | * [[Platelet aggregation]] | ||
[[Category:Antiplatelet drugs]] | [[Category:Antiplatelet drugs]] | ||
[[Category: | [[Category:Thiazoles]] | ||
[[Category:Piperazines]] | |||
Latest revision as of 01:47, 7 March 2025
A novel antiplatelet drug
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (2S)-2-[[4-[[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]piperazin-1-yl]methyl]-4-methyl-1,3-thiazole-5-carboxylic acid
| image = Selatogrel.svg
| image_size = 200px
| image_alt = Chemical structure of Selatogrel
}}
Selatogrel is a novel antiplatelet drug that acts as a P2Y12 receptor antagonist. It is being developed for the treatment of acute coronary syndrome (ACS) and other conditions where inhibition of platelet aggregation is desired.
Mechanism of Action[edit]
Selatogrel works by selectively inhibiting the P2Y12 receptor, a key receptor involved in the activation of platelets. By blocking this receptor, selatogrel prevents the binding of adenosine diphosphate (ADP), a potent platelet activator, thereby reducing platelet aggregation and thrombus formation.
Pharmacokinetics[edit]
Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug is designed to provide quick and effective platelet inhibition, which is crucial in the acute management of thrombotic events.
Clinical Development[edit]
Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. Preliminary studies have shown promising results, with rapid onset of action and significant inhibition of platelet aggregation.
Potential Benefits[edit]
The rapid action of selatogrel makes it a potentially valuable option in emergency settings where quick platelet inhibition is necessary. Its subcutaneous route of administration offers a convenient alternative to oral antiplatelet agents, especially in patients who are unable to take oral medications.
Side Effects[edit]
As with other antiplatelet agents, the primary side effect of selatogrel is an increased risk of bleeding. Other potential side effects include bruising, nausea, and headache.
